Regarding: Increased fracture risk after discontinuation of anti‐osteoporosis medications among hip fracture patients.

Perhaps dual-energy X-ray absorptiometry based bone mineral density (BMD) can act as a predictor for fracture risk to avoid interindividual differences in drug response, especially signs such as BMD changes that are strongly associated with vertebral fractures [4]. Keywords: anti-osteoporosis medication; bisphosphonates; denosumab; NHIRD EN anti-osteoporosis medication bisphosphonates denosumab NHIRD 384 385 2 02/22/22 20220301 NES 220301 We have carefully read the cohort study by Fu et al. on anti-osteoporosis medication (AOM) [1]. Regarding: Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients. [Extracted from the article]